S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
1970’s computer coder issues shocking A.I. warning (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
1970’s computer coder issues shocking A.I. warning (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
1970’s computer coder issues shocking A.I. warning (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
The Next Nvidia? (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
1970’s computer coder issues shocking A.I. warning (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
NASDAQ:DEPO

Depomed (DEPO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free DEPO Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$7.09
▼
$7.42
50-Day Range
N/A
52-Week Range
$4.31
▼
$9.48
Volume
940,193 shs
Average Volume
1.30 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
DEPO stock logo

About Depomed Stock (NASDAQ:DEPO)

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

DEPO Stock News Headlines

October 30, 2023 | finance.yahoo.com
Vulvodynia Treatment Market Size and Growth Analysis | Future Trends Analysis and Revenue Status 2023-2030
August 29, 2023 | thestreet.com
Horizon Pharma (HZNP) Stock Sinks After DepoMed Rejects Unsolicited $3 Billion Bid
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
August 13, 2023 | thestreet.com
Why DepoMed (DEPO) Stock Is Gaining Today
July 31, 2023 | finance.yahoo.com
Surge in Chronic Disorders Fuels Expansion of Global Tapentadol Market, Projected to Hit USD 5.32 Billion by 2028
July 8, 2023 | thestreet.com
Opioid Litigants Get Boost From Senate Report
May 17, 2023 | marketwatch.com
Chronic Fatigue Syndrome Therapeutics Drug Market Till 2030
May 12, 2023 | marketwatch.com
Pain Management Market Size, Outlook, Trends, Share by 2030
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
May 11, 2023 | marketwatch.com
Global Neuropathy Pain Treatment Market [2023] | Industry Set to Expand with Strong 3.4% CAGR and Reach USD 10560 Million by 2030
May 10, 2023 | msn.com
How Turkey's opposition is taking the taboo out of the headscarf debate
April 29, 2023 | marketwatch.com
Global Gabapentin Market by Size, Scope 2023: with Development Status 2031
April 23, 2023 | marketwatch.com
2023-2030 Chronic Pain Management Drugs Market Size with Manufactures and Upcoming Opportunities
April 17, 2023 | thestreet.com
Depomed, Insys Shares Down After FDA Decision on Endo's Opana ER
April 15, 2023 | marketwatch.com
Peripheral Neuritis Treatment research report leads towards the developing of this industry with an estimated CAGR 11.1% during 2023-2030
April 13, 2023 | marketwatch.com
Neuropathy Pain Treatment Market Growth Prediction and Segment Insight 2023-2107
April 5, 2023 | marketwatch.com
Neuropathy Pain Treatment Market 2023 Size and Forecast to 2031
March 30, 2023 | marketwatch.com
Vulvodynia Treatment Market: Overview of the Regional Outlook 2023-2030
March 14, 2023 | marketwatch.com
Pain Management Market Size, Growth | Soaring Demand | 2023 - 2029
March 13, 2023 | marketwatch.com
Pain Relief Medications Market Research Report 2023-2028 with Top Countries Data
February 21, 2023 | marketwatch.com
Diabetic Neuropathy Treatment Market 2023 Exploring New Challenges and Opportunities, Forecast to 2028
February 3, 2023 | marketwatch.com
Controlled Release Drug Delivery Market 2023 Expected to Reach Significant Rate by 2029
January 29, 2023 | marketwatch.com
Neuropathy Pain Treatment Market Growth, Size, Share, Opportunities, Industry Analysis and Forecast 2023 To 2028
January 23, 2023 | thestreet.com
CFO Says Depomed to Buy or Be Sold
January 3, 2023 | marketwatch.com
Neuropathic Pain Management Market Size, Share and Forecast 2028 with Top Countries Data
October 15, 2022 | newsweek.com
J.D. Vance Cancels Fundraiser Planned by Doctor Mentioned in Opioid Lawsuit - Newsweek
October 12, 2022 | marketwatch.com
Pain Management Drugs Market is Growing Worldwide | 133 Report Pages
See More Headlines
Receive DEPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Depomed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/08/2018
Today
4/18/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:DEPO
CUSIP
24990810
CIK
1005201
Web
www.depomedinc.com
Phone
(224) 419-7106
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2024 Cover
The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Daniel A. Peisert
    President, Chief Executive Officer & Director
  • Paul Schwichtenberg
    Chief Financial Officer & Senior Vice President
  • Ajay Patel
    Chief Accounting Officer & Senior Vice President
  • Megan C. Timmins
    Secretary, Senior Vice President & General Counsel
  • Max Nemmers
    Head-Investor Relations & Administration

Key Competitors

View All Competitors

DEPO Stock Analysis - Frequently Asked Questions

How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) announced its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.03. The specialty pharmaceutical company earned $63.27 million during the quarter, compared to analyst estimates of $63.72 million. The firm's revenue for the quarter was down 37.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.08 earnings per share.

What other stocks do shareholders of Depomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Depomed investors own include Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Vertex Pharmaceuticals (VRTX), MercadoLibre (MELI), Alphabet (GOOG), Horizon Therapeutics Public (HZNP), Bausch Health Companies (BHC), Gilead Sciences (GILD), Allergan (AGN) and Bristol-Myers Squibb (BMY).

This page (NASDAQ:DEPO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts